Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
08/31/2015 09/01/2015 09/02/2015 09/03/2015 09/04/2015 Date
0.97(c) 0.99(c) 0.96(c) 0.97(c) 0.94 Last
694 085 2 791 884 392 280 150 729 134 092 Volume
+1.04% +2.06% -3.03% +1.04% -3.09% Change
More quotes
Financials (€)
Sales 2015 5,03 M
EBIT 2015 -6,03 M
Net income 2015 -6,65 M
Debt 2015 1,06 M
Yield 2015 -
Sales 2016 0,05 M
EBIT 2016 -10,0 M
Net income 2016 -6,65 M
Debt 2016 8,35 M
Yield 2016 34,4%
PER 2015 -
PER 2016
EV / Sales 2015 6,40x
EV / Sales 2016 789x
Capitalization 31,1 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis, and... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating :
More Ratings
Latest news on NEOVACS
09/02 NEOVACS : Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kino..
09/02 NEOVACS : RECEIVES FIRST REGULATORY APPROVALS FOR A PHASE IIb TRIAL OF IFNα-KIN..
09/01 NEOVACS : receives first regulatory approvals for a phase IIb trial in lupus
09/01 NEOVACS : receives first regulatory approvals for a Phase IIb trial of IFNalpha-..
09/01 NEOVACS : RECEIVES FIRST REGULATORY APPROVALS FOR A PHASE IIb TRIAL OF IFN&alpha..
08/15 STELLAR BIOTECHNOLOGIES : Updates on Third Quarter 2015 Financial Results and Op..
08/13 STELLAR BIOTECHNOLOGIES : Posts Third Quarter 2015 Financial Results and Operati..
08/10 NEOVACS : Stellar Biotechnologies Reports Third Quarter 2015 Financial Results a..
More news
Sector news : Biotechnology & Medical Research - NEC
09/03 MEDIVATION : Announces Participation at Upcoming Investor Conference
09/03 QUINTILES TRANSNATIONAL : CEO to Present at Morgan Stanley Global Healthcare Con..
09/03 QIAGEN NV : kit isolates high-quality RNA from exosomes in liquid biopsies
More sector news : Biotechnology & Medical Research - NEC


Comments 
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions